Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 8c; Cash and Cash Equivalents of $240.3M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results
November 4, 2021 7:00 AM EDTOn-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease
Losmapimod update planned for Q1 2022
Raised $144.2 million in gross proceeds from August 2021 public offering, extending cash runway into 2024
Conference call scheduled for 8:00 a.m. ET today
CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business... More
